Loading
A phase 2 trial of Carfilzomib, Venetoclax, Dexamethasone in multiple myeloma, run by AbbVie, active and no longer recruiting.
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) is a phase 2 interventional study registered as NCT02899052 by AbbVie, with 120 participants planned, started 2017-01-19 and due to reach its primary completion in 2027-06. Interventions recorded: Carfilzomib, Venetoclax, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone.
Shares BCL-2 inhibitors, Relapsed or refractory multiple myeloma, Venetoclax, Multiple myeloma.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, BCL-2 inhibitors, Dexamethasone.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Carfilzomib, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.